Study of Transcatheter Aortic Valve Replacement With A² Flex and Commissural Alignment Technology in Severe Aortic Stenosis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorPeijia Medical Technology (Suzhou) Co., Ltd.

About this trial

A prospective, single-center, single-group follow-up study of transcatheter aortic valve replacement with A² Flex and commissural alignment technology in severe aortic stenosis by Peijia Medical

Eligibility criteria

Qualifiers

Patients who are willing to participate and sign the informed consent and can cooperate with the whole trial process;

Age ≥60 years old;

Patients with severe calcified aortic stenosis confirmed by echocardiography (trans-aortic valve flow velocity ≥ 4.0m /s, or trans-active valvular pressure difference ≥40mmHg (1mmHg=0.133kPa), or aortic valve orientation area < 0.8cm2, or effective aortic valve orifice the product index is < 0.5cm2/m2);

The cardiac team (at least two specialists in cardiovascular surgery) assessed the patient as unsuitable for routine surgery ;

Disqualifiers

The left and right coronary ostiums originate from the junctional zone or from both coronary ostiums;

previous CABG history;

Coronary ostial lesions(PCI or not);

Prior aortic valve prosthesis implantation (interventional/surgical, bioprosthetic/mechanical);

Trial design

Treatments tested in this trial

  • transcatheter aortic valve replacement in severe aortic stenosis

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators

Peijia Medical Technology (Suzhou) Co., Ltd.

Lead sponsor

Shanghai Zhongshan Hospital

Collaborator